Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

Anavex schedules an investor call as it restores SEC filing currency and NASDAQ listing compliance.

Rhea-AI Summary

Anavex Life Sciences (AVXL) will host an investor conference call on Wednesday, September 9, 2026, at 4:00 PM ET.

Interim CEO Terrie Kellmeyer, Ph.D., will discuss the company’s clinical development strategy and priorities. The live webcast and replay will be available via the investor relations section of anavex.com, with phone access for U.S./Canada at 1-866-777-2509 and international at 1-412-317-5413. The company is now current on SEC financial reporting and, as of September 2, 2026, has regained compliance with NASDAQ listing rules after filing its outstanding Form 10-Qs for the second and third fiscal quarters of 2026.

Positive

• Investor call scheduled for 4:00 PM ET on September 9, 2026
• Current on SEC financial reporting after filing outstanding FY2026 Q2 and Q3 Form 10-Qs
• Regained NASDAQ listing compliance effective September 2, 2026

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company’s clinical development strategy and priorities.

Anavex Investor Call Information:

• A link to the live webcast of the conference call will be available on Anavex’s investor relations website at anavex.com/investors.
• The conference call can also be accessed by dialing 1-866-777-2509 for participants in the U.S. and Canada or 1-412-317-5413 for international participants. Participants should ask to join the Anavex call.
• A replay of the conference call will be available at anavex.com/investors shortly after the end of the call.
  

The Company is now current on its financial reporting obligations with the Securities and Exchange Commission and, on September 2, 2026, officially regained compliance with NASDAQ listing rules as a result of filing its outstanding Form 10-Qs for the second and third fiscal quarters for 2026.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.

Investor Relations & Media Contact:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

Company Contact:

Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email: ir@anavexcorp.com

FAQ

How can investors access the Anavex investor call on September 9, 2026?

The call can be accessed via a live webcast on the investor relations section of anavex.com/investors. Phone participants in the U.S. and Canada can dial 1-866-777-2509, while international participants can dial 1-412-317-5413 and ask to join the Anavex call.

Will a replay of the Anavex investor call be available?

Yes. A replay of the conference call will be available shortly after the end of the call at anavex.com/investors.

What topics will be discussed during the Anavex investor call?

Interim CEO Terrie Kellmeyer, Ph.D., will discuss Anavex’s clinical development strategy and priorities.

What recent regulatory and listing status changes has Anavex disclosed?

Anavex is now current on its financial reporting obligations with the SEC and, on September 2, 2026, officially regained compliance with NASDAQ listing rules after filing its outstanding Form 10-Qs for the second and third fiscal quarters of 2026.